Keyphrases
Organoids
100%
Primary Hepatocytes
99%
Liver
48%
Human Liver
47%
Hepatocytes
44%
Liver Function
40%
Hepatotoxicity
34%
Cas9 Protein
34%
Hepatocyte Spheroid
34%
Drug Screening
31%
Liver Disease
30%
Secretome
28%
Enteroendocrine Cells
28%
High-resolution
28%
Drug Candidates
24%
In Vitro Model
23%
Drug-induced Liver Injury
23%
Drug Toxicity
22%
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
20%
Drug Metabolism
19%
Adult Stem Cells
18%
Human Hepatocytes
18%
Cytochrome P450 3A4 (CYP3A4)
18%
Hepatocyte-like Cells
17%
Microfluidics
17%
Bile Acids
16%
Hepatic Spheroid
16%
Genetic Engineering
16%
Drug-induced Cholestasis
16%
Organoid Models
16%
Human-relevant
16%
Etiology
16%
Human Fetal Hepatocytes
16%
3D Spheroids
16%
Gene Knockout
16%
Multiplexing
16%
Homology-independent
16%
Hepatocyte Model
16%
Dedifferentiation
15%
Fialuridine
15%
Steatosis
15%
Hepatocyte Dedifferentiation
15%
3D Spheroid Models
15%
Ximelagatran
14%
Cellular microRNAs
14%
Transcriptome Comparison
14%
Experimental Application
14%
Three-dimensional Spheroid Culture
14%
CYP3A4 Induction
14%
Induction Mechanism
14%
Medicine and Dentistry
Organoid
98%
Hepatocyte
94%
Clustered Regularly Interspaced Short Palindromic Repeat
46%
Tumor Spheroid
42%
Cas9
31%
In Vitro
28%
Genome Editing
16%
Drug Toxicity
15%
CYP3A4
15%
Cell Transdifferentiation
14%
Lipogenesis
14%
Metabolic Activation
14%
Ximelagatran
14%
Carcinoma
14%
Gene Knockin
14%
Genetic Engineering
14%
Drug Metabolism
14%
Liver Disease
14%
Stem Cell
14%
Drug Screening
14%
Mitogenic Agent
14%
Adipocyte
8%
Transgenesis
7%
Liver Toxicity
7%
Vascularity
7%
Grafting
7%
Disease
6%
Liver Function
5%
Central Nervous System
5%
Triacylglycerol
5%
Genome Engineering
5%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatotoxicity
50%
Toxic Hepatitis
28%
CYP3A4
23%
Liver Disease
23%
Cholestasis
21%
Disease
21%
Drug Toxicity
20%
Fialuridine
18%
Drug Metabolism
18%
Bile Acid
18%
Drug Screening
16%
Chlorpromazine
15%
Mefenamic Acid
14%
Reduced Nicotinamide Adenine Dinucleotide (Phosphate) Dehydrogenase (Quinone)
14%
Diclofenac
14%
Carcinoma
14%
Nonalcoholic Fatty Liver
14%
Cosmetic
14%
Animal Testing
14%
Liver Fibrosis
14%
Risk Evaluation
14%
Ximelagatran
14%
Therapeutic Use
14%
Safety Assessment
14%
Transcriptome
14%
Messenger RNA
14%
Toxicology
14%
Cell Culture
11%
Absorption Distribution Metabolism Excretion
9%
Troglitazone
9%
Hepatotoxin
9%
Fatty Acid
7%
Apolipoprotein B
7%
Albumin
7%
Adenosine Triphosphate
7%
Pharmacotherapy
7%
Long Term Exposure
6%
Drug Development
5%
Triacylglycerol
5%
